Pfizer and Valeant both posted brand valuation increases greater than 30% in this year's Brand Finance ranking.
Newsmaker pharmas Pfizer and Valeant Pharmaceuticals both saw brand valuation increases of more than 30% in this year's Brand Finance ranking.
Drug companies can't currently help Medicare patients pay for out-of-pocket drug costs. But Valeant, which has come under the lens for its price-hike strategy, wants to change that.
Pharma eyes are watching Capitol Hill on Thursday, where drug-price hikes will go on trial in a much-publicized congressional committee hearing. Valeant interim CEO Howard Schiller and ex-Turing Pharmaceuticals chief Martin Shkreli will get a grilling, though Schiller is the only one expected to answer any questions.
Valeant's Bausch + Lomb has voluntarily initiated a massive recall of an eye dilation med after learning that more than 1 million bottles may have been shipped with the wrong medication insert.
Interim Valeant CEO Howard Schiller has taken the reins at a tough time for the company. But the way the company sees it, he's reaping an appropriate reward.
Later this week, former Turing Pharmaceuticals CEO Martin Shkreli and interim Valeant CEO Howard Schiller will appear before Congress to answer for their companies' mammoth price increases. They'll also have to answer for the methods they used to draw attention away from those hikes.
PBM giant Express Scripts has long been a leader in the fight to tamp down drug prices, and now, it's using its formulary power to freeze out a diabetes drug from controversial Valeant.
Big Pharma can celebrate a bright point. Arizona's top court ruled that drugmakers don't have an obligation to warn patients directly about safety risks of their meds. Raising those warnings with doctors is enough, the court determined.
Valeant's pneumonia-stricken CEO, J. Michael Pearson, is on the mend, according to a letter he penned to his colleagues on Monday. But as to when he'll be back at work, it's still up in the air.